UK Sanders-Brown Center on Aging

The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of a promising drug known as lecanemab. Just a few weeks ago the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. This represents an important advancement in the ongoing fight to effectively treat Alzheimer’s disease, and UK’s Sanders-Brown Center on Aging is on the forefront of the work. Dr. Greg speaks with Greg Jicha, director of clinical trials at UK’s Sanders-Brown Center on Aging.

The University of Kentucky has officially opened a new state-of-the-art facility dedicated to memory care. WUKY’s Karyn Czar reports.

The University of Kentucky is set to take part in a landmark clinical trial on an experimental Alzheimer’s drug. Researchers hope to enroll a thousand…

LEXINGTON, Ky. - Each year around 5,000 babies are born in the United States with Down syndrome, a genetic disorder that can impair mental abilities and…